1586 related articles for article (PubMed ID: 7554977)
41. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
42. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
43. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
45. Hormonal and menstrual changes after laparoscopic sterilization by Falope-rings or Filshie-clips.
Thranov I; Hertz JB; Kjer JJ; Andresen A; Micic S; Nielsen J; Hancke S
Fertil Steril; 1992 Apr; 57(4):751-5. PubMed ID: 1532561
[TBL] [Abstract][Full Text] [Related]
46. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
47. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
[TBL] [Abstract][Full Text] [Related]
48. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
49. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
50. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
51. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability.
Tang GW; Lo SS
Contraception; 1995 Apr; 51(4):231-5. PubMed ID: 7796588
[TBL] [Abstract][Full Text] [Related]
52. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
[TBL] [Abstract][Full Text] [Related]
53. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
54. Response to intermittent RU486 in women.
Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
[TBL] [Abstract][Full Text] [Related]
55. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
56. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
58. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
[TBL] [Abstract][Full Text] [Related]
59. Hormonal evaluation of the intrauterine progesterone contraceptive system.
Bryand-Greenwood GD; Greenwood FC; Hale RW; Morishige WK
J Clin Endocrinol Metab; 1977 Apr; 44(4):721-7. PubMed ID: 849982
[TBL] [Abstract][Full Text] [Related]
60. Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and follicular development.
Brache V; Alvarez F; Faundes A; Cochon L; Thevenin F
Fertil Steril; 1996 Jun; 65(6):1110-4. PubMed ID: 8641481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]